NCT00625456 - Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

June 30, 2014

Conditions

MelanomaLung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Intravenous Dosage from 1 x 10\^5 pfu/kg to 3 x 10\^7 pfu/kg Intravenous infusion is administered once over a 60 minute period

Trial Locations (4)

Cancer Centers of the Carolinas, Greenville

Billings Clinic, Billings

University of Pennsylvania, Philadelphia

Ottawa Health Research Institute, Ottawa